Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Premature Labor Market 2016 Share, Trend, Segmentation and Forecast to 2022

Monday, October 10, 2016 4:06
% of readers think this story is Fact. Add your two cents.

(Before It's News)


Global Markets Direct’s, ‘Premature Labor (Tocolysis) – Pipeline Review, H2 2016’, provides an overview of the Premature Labor (Tocolysis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.

Complete report details @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) 
- The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects 
- The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)

Request a sample report @

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis) 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @


Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Global Markets Direct Report Coverage 6 
Premature Labor (Tocolysis) Overview 7 
Therapeutics Development 8 
Pipeline Products for Premature Labor (Tocolysis) – Overview 8 
Pipeline Products for Premature Labor (Tocolysis) – Comparative Analysis 9 
Premature Labor (Tocolysis) – Therapeutics under Development by Companies 10 
Premature Labor (Tocolysis) – Therapeutics under Investigation by Universities/Institutes 11 
Premature Labor (Tocolysis) – Pipeline Products Glance 12 
Late Stage Products 12 
Clinical Stage Products 13 
Early Stage Products 14 
Unknown Stage Products 15 
Premature Labor (Tocolysis) – Products under Development by Companies 16 
Premature Labor (Tocolysis) – Products under Investigation by Universities/Institutes 17 
Premature Labor (Tocolysis) – Companies Involved in Therapeutics Development 18 
AMAG Pharmaceuticals, Inc. 18 
GlaxoSmithKline Plc 19 
Juniper Pharmaceuticals, Inc. 20 
Kissei Pharmaceutical Co., Ltd. 21 
Lipocine Inc. 22 
ObsEva SA 23 
Premature Labor (Tocolysis) – Therapeutics Assessment 24 
Assessment by Monotherapy Products 24 
Assessment by Target 25 
Assessment by Mechanism of Action 27 
Assessment by Route of Administration 29 
Assessment by Molecule Type 31 
Drug Profiles 32 
bedoradrine sulfate – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
hydroxyprogesterone caproate – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
hydroxyprogesterone caproate – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
OBE-001 – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
OBE-022 – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
progesterone – Drug Profile 41 
Product Description 41 
Mechanism Of Action 41 
R&D Progress 41 
retosiban – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
Small Molecule for Acute Inflammation and Premature Labor – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
Small Molecule to Agonize Progesterone Receptor for Preterm Birth – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
Small Molecules for Premature Labor – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
Premature Labor (Tocolysis) – Dormant Projects 46 
Premature Labor (Tocolysis) – Discontinued Products 47 
Premature Labor (Tocolysis) – Product Development Milestones 48 
Featured News & Press Releases 48 
Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor 48 
Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 48 
Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 49 
Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women 50 
Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301 50 
Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena 51 
Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection) 51 
Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor 52 
Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways 52 
Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study – Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women 53 
May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena 54 
May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth 54 
Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour 55 
Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour 56 
Jul 02, 2012: FDA Issues Further Guidance On K-V Pharma’s Makena 56 
Appendix 59 
Methodology 59 
Coverage 59 
Secondary Research 59 
Primary Research 59 
Expert Panel Validation 59 
Contact Us 59 
Disclaimer 6

List of Tables 
Number of Products under Development for Premature Labor (Tocolysis), H2 2016 8 
Number of Products under Development for Premature Labor (Tocolysis) – Comparative Analysis, H2 2016 9 
Number of Products under Development by Companies, H2 2016 10 
Number of Products under Investigation by Universities/Institutes, H2 2016 11 
Comparative Analysis by Late Stage Development, H2 2016 12 
Comparative Analysis by Clinical Stage Development, H2 2016 13 
Comparative Analysis by Early Stage Development, H2 2016 14 
Comparative Analysis by Unknown Stage Development, H2 2016 15 
Products under Development by Companies, H2 2016 16 
Products under Investigation by Universities/Institutes, H2 2016 17 
Premature Labor (Tocolysis) – Pipeline by AMAG Pharmaceuticals, Inc., H2 2016 18 
Premature Labor (Tocolysis) – Pipeline by GlaxoSmithKline Plc, H2 2016 19 
Premature Labor (Tocolysis) – Pipeline by Juniper Pharmaceuticals, Inc., H2 2016 20 
Premature Labor (Tocolysis) – Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 21 
Premature Labor (Tocolysis) – Pipeline by Lipocine Inc., H2 2016 22 
Premature Labor (Tocolysis) – Pipeline by ObsEva SA, H2 2016 23 
Assessment by Monotherapy Products, H2 2016 24 
Number of Products by Stage and Target, H2 2016 26 
Number of Products by Stage and Mechanism of Action, H2 2016 28 
Number of Products by Stage and Route of Administration, H2 2016 30 
Number of Products by Stage and Molecule Type, H2 2016 31 
Premature Labor (Tocolysis) – Dormant Projects, H2 2016 46 
Premature Labor (Tocolysis) – Discontinued Products, H2 2016 47

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.